Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Rating) major shareholder Ecor1 Capital, Llc acquired 376,000 shares of the business’s stock in a transaction dated Thursday, June 23rd. The shares were bought at an average cost of $5.66 per share, with a total value of $2,128,160.00. Following the transaction, the insider now directly owns 4,753,907 shares of the company’s stock, valued at approximately $26,907,113.62. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Ecor1 Capital, Llc also recently made the following trade(s):
- On Tuesday, June 21st, Ecor1 Capital, Llc acquired 101,400 shares of Voyager Therapeutics stock. The shares were bought at an average cost of $5.28 per share, with a total value of $535,392.00.
NASDAQ:VYGR traded up $0.88 during mid-day trading on Thursday, hitting $5.84. The company’s stock had a trading volume of 776,624 shares, compared to its average volume of 619,604. Voyager Therapeutics, Inc. has a fifty-two week low of $2.46 and a fifty-two week high of $10.60. The company has a market capitalization of $224.58 million, a price-to-earnings ratio of -2.83 and a beta of 1.10. The stock has a fifty day moving average of $6.53 and a 200-day moving average of $5.22.
Several hedge funds and other institutional investors have recently bought and sold shares of VYGR. EcoR1 Capital LLC acquired a new stake in shares of Voyager Therapeutics during the third quarter worth approximately $1,173,000. Walleye Capital LLC acquired a new stake in shares of Voyager Therapeutics during the first quarter worth approximately $1,148,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Voyager Therapeutics by 359.2% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 147,534 shares of the company’s stock worth $400,000 after buying an additional 115,404 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Voyager Therapeutics by 241.2% during the first quarter. Goldman Sachs Group Inc. now owns 113,560 shares of the company’s stock valued at $865,000 after purchasing an additional 80,277 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Voyager Therapeutics by 620.2% during the first quarter. Bank of America Corp DE now owns 87,867 shares of the company’s stock valued at $669,000 after purchasing an additional 75,666 shares during the last quarter. 46.16% of the stock is owned by institutional investors.
A number of research analysts have recently commented on the stock. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, April 30th. Chardan Capital upped their price objective on shares of Voyager Therapeutics from $4.00 to $6.00 in a research report on Wednesday, March 9th.
Voyager Therapeutics Company Profile (Get Rating)
Voyager Therapeutics, Inc, a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.
- Get a free copy of the StockNews.com research report on Voyager Therapeutics (VYGR)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.